JP2007537704A - ヒト化免疫グロブリン遺伝子座 - Google Patents
ヒト化免疫グロブリン遺伝子座 Download PDFInfo
- Publication number
- JP2007537704A JP2007537704A JP2006520411A JP2006520411A JP2007537704A JP 2007537704 A JP2007537704 A JP 2007537704A JP 2006520411 A JP2006520411 A JP 2006520411A JP 2006520411 A JP2006520411 A JP 2006520411A JP 2007537704 A JP2007537704 A JP 2007537704A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- human
- sequence
- nucleic acid
- humanized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 C[C@](*C1)[C@]1(C(C)C(C1)N)[*+]1C1CC1 Chemical compound C[C@](*C1)[C@]1(C(C)C(C1)N)[*+]1C1CC1 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48773303P | 2003-07-15 | 2003-07-15 | |
| PCT/US2004/023226 WO2005007696A2 (en) | 2003-07-15 | 2004-07-15 | Humanized immunoglobulin loci |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011131898A Division JP6017763B2 (ja) | 2003-07-15 | 2011-06-14 | ヒト化免疫グロブリン遺伝子座 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007537704A true JP2007537704A (ja) | 2007-12-27 |
Family
ID=34079388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006520411A Withdrawn JP2007537704A (ja) | 2003-07-15 | 2004-07-15 | ヒト化免疫グロブリン遺伝子座 |
| JP2011131898A Expired - Lifetime JP6017763B2 (ja) | 2003-07-15 | 2011-06-14 | ヒト化免疫グロブリン遺伝子座 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011131898A Expired - Lifetime JP6017763B2 (ja) | 2003-07-15 | 2011-06-14 | ヒト化免疫グロブリン遺伝子座 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US7585668B2 (enExample) |
| EP (1) | EP1644417B1 (enExample) |
| JP (2) | JP2007537704A (enExample) |
| CN (2) | CN103205436B (enExample) |
| AU (1) | AU2004257292A1 (enExample) |
| CA (1) | CA2532117C (enExample) |
| ES (1) | ES2473596T3 (enExample) |
| IL (1) | IL172885A0 (enExample) |
| MX (1) | MXPA06000562A (enExample) |
| WO (1) | WO2005007696A2 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011516071A (ja) * | 2008-04-10 | 2011-05-26 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト (ゲーエムベーハー) | シス作用性多様化活性化因子および核酸の選択的多様化のための方法 |
| JP2014529998A (ja) * | 2011-09-19 | 2014-11-17 | カイマブ・リミテッド | ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖 |
| JP2020150951A (ja) * | 2009-07-08 | 2020-09-24 | カイマブ・リミテッド | 動物モデルおよび治療用分子 |
| JP2021516954A (ja) * | 2018-03-21 | 2021-07-15 | クリスタル バイオサイエンス インコーポレイテッドCrystal Bioscience Inc. | ヒト型抗体を産生するトランスジェニックニワトリ |
| JP2023508290A (ja) * | 2019-12-18 | 2023-03-02 | ブリストル-マイヤーズ スクイブ カンパニー | 共通のリーダー配列を有するbcrトランスジェニックマウス |
| KR102964498B1 (ko) | 2018-03-21 | 2026-05-12 | 크리스탈 바이오사이언스 주식회사 | 인간 항체를 생산하는 트랜스제닉 닭 |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN103205436B (zh) * | 2003-07-15 | 2016-05-25 | 人类多克隆治疗公司 | 人源化免疫球蛋白基因座 |
| US20100034782A1 (en) * | 2006-05-31 | 2010-02-11 | Nader Najafian | Methods of Using Anti-Thymocyte Globulin and Related Agents |
| ES2378407T3 (es) * | 2006-09-01 | 2012-04-12 | Therapeutic Human Polyclonals, Inc. | Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos |
| US20090053210A1 (en) | 2006-09-01 | 2009-02-26 | Roland Buelow | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| CA2688834C (en) | 2007-06-01 | 2020-01-07 | Ronald Buelow | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
| WO2009097006A2 (en) * | 2007-08-10 | 2009-08-06 | Medarex, Inc. | Hco32 and hco27 and related examples |
| WO2009023800A1 (en) * | 2007-08-14 | 2009-02-19 | Origen Therapeutics | Transgenic chickens with an inactivated endogenous gene locus |
| CA2747534C (en) * | 2008-12-18 | 2020-08-18 | Erasmus University Medical Center Rotterdam | Non-human transgenic animals expressing humanised antibodies and use therof |
| US8592644B2 (en) * | 2009-08-13 | 2013-11-26 | Crystal Bioscience Inc. | Transgenic animal for production of antibodies having minimal CDRS |
| US8865462B2 (en) | 2010-01-20 | 2014-10-21 | Crystal Bioscience Inc. | Sustained culture of avian gonocytes |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| HRP20151188T4 (hr) | 2010-02-08 | 2021-10-01 | Regeneron Pharmaceuticals, Inc. | Miš sa zajedničkim lakim lancem |
| PL3251503T3 (pl) * | 2010-03-31 | 2024-07-08 | Ablexis, Llc | Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych |
| SI2480675T1 (sl) | 2010-06-22 | 2016-08-31 | Regeneron Pharmaceuticals, Inc. | Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo |
| KR102306967B1 (ko) | 2010-08-02 | 2021-10-01 | 리제너론 파아마슈티컬스, 인크. | Vl 도메인을 포함하는 결합 단백질을 생성하는 마우스 |
| CN102250239B (zh) * | 2011-06-13 | 2013-04-17 | 中国农业科学院哈尔滨兽医研究所 | 一种与兔出血症病毒vp60蛋白相结合的蛋白及其应用 |
| PT3865581T (pt) | 2011-08-05 | 2024-10-04 | Regeneron Pharma | Murganhos da cadeia leve universal humanizada |
| KR20140082824A (ko) | 2011-10-17 | 2014-07-02 | 리제너론 파아마슈티컬스, 인크. | 제한된 면역글로불린 중쇄 마우스 |
| PT3527070T (pt) | 2011-12-20 | 2025-12-19 | Regeneron Pharma | Murganhos de cadeia leve humanizada |
| CN104011080B (zh) | 2011-12-22 | 2017-10-20 | 弗·哈夫曼-拉罗切有限公司 | 用于真核细胞的全长抗体展示系统及其用途 |
| NZ810648A (en) * | 2012-02-01 | 2025-11-28 | Regeneron Pharma | Humanized rodents that express heavy chains containing vl domains |
| DK2825036T3 (en) | 2012-03-16 | 2018-07-16 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified rodents to generate them |
| KR102213535B1 (ko) | 2012-03-16 | 2021-02-08 | 리제너론 파마슈티칼스 인코포레이티드 | pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물 |
| EP3912464A1 (en) | 2012-06-12 | 2021-11-24 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
| KR102159163B1 (ko) | 2012-08-03 | 2020-09-23 | 에스에이비, 엘엘씨 | 유전자삽입 동물에서 인간 항체의 제조를 위한 복합 염색체 조작 |
| MY185881A (en) | 2013-02-20 | 2021-06-14 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
| EP4218409B1 (en) * | 2013-03-13 | 2025-02-12 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| JP2016519568A (ja) * | 2013-03-13 | 2016-07-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 共通軽鎖のマウス |
| US20170101460A1 (en) * | 2014-01-10 | 2017-04-13 | Allermabs Co. Ltd. | Transgenic animals capable of producing humanized ige at much higher levels than mouse ige |
| CN106164092A (zh) | 2014-03-21 | 2016-11-23 | 瑞泽恩制药公司 | 表现不同结合特征的vl抗原结合蛋白 |
| CN106255410B (zh) | 2014-03-21 | 2020-01-10 | 瑞泽恩制药公司 | 产生单结构域结合蛋白的非人动物 |
| CN112877292A (zh) * | 2014-05-02 | 2021-06-01 | 凯奥目生物科学株式会社 | 产生人抗体的细胞 |
| US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| CN113862300A (zh) * | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
| PT4082334T (pt) * | 2016-11-04 | 2025-05-21 | Regeneron Pharma | Animais não humanos possuindo um lócus da cadeia leve lambda de immunoglobulina geneticamente modificada |
| CN110149809B (zh) | 2016-12-05 | 2023-04-14 | 皇家飞利浦有限公司 | 无线功率传输系统中的异物检测 |
| US12016313B2 (en) * | 2017-01-19 | 2024-06-25 | Omniab Operations, Inc. | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
| WO2019129679A1 (en) | 2017-12-29 | 2019-07-04 | F. Hoffmann-La Roche Ag | Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody |
| EP3990492A1 (en) | 2019-06-27 | 2022-05-04 | F. Hoffmann-La Roche AG | Novel icos antibodies and tumor-targeted antigen binding molecules comprising them |
| AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| CN110540996B (zh) * | 2019-08-29 | 2022-01-28 | 华中农业大学 | 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用 |
| CR20240246A (es) | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden |
| CN114854901B (zh) * | 2022-06-22 | 2025-11-07 | 华南农业大学 | 与苦瓜全雌性状共分离的分子标记、引物及其应用 |
| AU2024311339A1 (en) | 2023-06-21 | 2026-01-08 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002012437A2 (en) * | 2000-08-03 | 2002-02-14 | Schooten Wim Van | Production of humanized antibodies in transgenic animals |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2066433A1 (en) | 1990-07-10 | 1992-01-11 | Haruo Matsuda | Chicken-specific immunoglobulin g-producing hybridoma |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0583980A1 (en) | 1992-08-20 | 1994-02-23 | Eli Lilly And Company | Method for generating monoclonal antibodies from rabbits |
| WO1997016537A1 (en) | 1995-10-30 | 1997-05-09 | Spectral Diagnostics, Inc. | Stable chicken b-cell line and method of use thereof |
| DE60023451T2 (de) | 1999-02-05 | 2006-07-20 | Therapeutic Human Polyclonals, Inc., Mountain View | Aus nicht-menschlichen transgenen tieren gewonnene menschliche polyklonale antikörper |
| WO2000075300A2 (en) | 1999-06-04 | 2000-12-14 | Tranxenogen, Inc. | Methods for manipulating the avian genome |
| WO2001019394A2 (en) | 1999-09-15 | 2001-03-22 | Therapeutic Human Polyclonals, Inc. | Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds |
| ATE430756T1 (de) | 2002-06-26 | 2009-05-15 | Transgenrx Inc | Genregulation in transgenen tieren unter verwendung eines vektors auf transposonbasis |
| CN103205436B (zh) * | 2003-07-15 | 2016-05-25 | 人类多克隆治疗公司 | 人源化免疫球蛋白基因座 |
| US20100286488A1 (en) | 2004-08-27 | 2010-11-11 | Moshe Cohen | Method and system for using a mobile device as a portable personal terminal for medical information |
| US20110077965A1 (en) | 2009-09-25 | 2011-03-31 | Cerner Innovation, Inc. | Processing event information of various sources |
| US20120306653A1 (en) | 2011-06-02 | 2012-12-06 | Nokia Siemens Networks Oy | Medical sensor |
| US20130021154A1 (en) | 2011-07-21 | 2013-01-24 | Solomon Clifford T | Medical parameters notification system |
-
2004
- 2004-07-15 CN CN201210390234.2A patent/CN103205436B/zh not_active Expired - Lifetime
- 2004-07-15 EP EP04778633.0A patent/EP1644417B1/en not_active Expired - Lifetime
- 2004-07-15 CA CA2532117A patent/CA2532117C/en not_active Expired - Lifetime
- 2004-07-15 ES ES04778633.0T patent/ES2473596T3/es not_active Expired - Lifetime
- 2004-07-15 WO PCT/US2004/023226 patent/WO2005007696A2/en not_active Ceased
- 2004-07-15 AU AU2004257292A patent/AU2004257292A1/en not_active Abandoned
- 2004-07-15 US US10/893,483 patent/US7585668B2/en active Active
- 2004-07-15 CN CNA2004800261928A patent/CN1852925A/zh active Pending
- 2004-07-15 JP JP2006520411A patent/JP2007537704A/ja not_active Withdrawn
- 2004-07-15 MX MXPA06000562A patent/MXPA06000562A/es unknown
-
2005
- 2005-12-29 IL IL172885A patent/IL172885A0/en unknown
-
2009
- 2009-07-29 US US12/511,188 patent/US8410333B2/en not_active Expired - Fee Related
-
2011
- 2011-06-14 JP JP2011131898A patent/JP6017763B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-27 US US13/779,585 patent/US8652842B2/en not_active Ceased
-
2016
- 2016-02-09 US US15/019,852 patent/USRE47131E1/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002012437A2 (en) * | 2000-08-03 | 2002-02-14 | Schooten Wim Van | Production of humanized antibodies in transgenic animals |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011516071A (ja) * | 2008-04-10 | 2011-05-26 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト (ゲーエムベーハー) | シス作用性多様化活性化因子および核酸の選択的多様化のための方法 |
| JP2020150951A (ja) * | 2009-07-08 | 2020-09-24 | カイマブ・リミテッド | 動物モデルおよび治療用分子 |
| JP7141427B2 (ja) | 2009-07-08 | 2022-09-22 | カイマブ・リミテッド | 動物モデルおよび治療用分子 |
| JP2014529998A (ja) * | 2011-09-19 | 2014-11-17 | カイマブ・リミテッド | ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖 |
| JP2021516954A (ja) * | 2018-03-21 | 2021-07-15 | クリスタル バイオサイエンス インコーポレイテッドCrystal Bioscience Inc. | ヒト型抗体を産生するトランスジェニックニワトリ |
| JP7779655B2 (ja) | 2018-03-21 | 2025-12-03 | クリスタル バイオサイエンス インコーポレイテッド | ヒト型抗体を産生するトランスジェニックニワトリ |
| KR102964498B1 (ko) | 2018-03-21 | 2026-05-12 | 크리스탈 바이오사이언스 주식회사 | 인간 항체를 생산하는 트랜스제닉 닭 |
| JP2023508290A (ja) * | 2019-12-18 | 2023-03-02 | ブリストル-マイヤーズ スクイブ カンパニー | 共通のリーダー配列を有するbcrトランスジェニックマウス |
| JP7716406B2 (ja) | 2019-12-18 | 2025-07-31 | ブリストル-マイヤーズ スクイブ カンパニー | 共通のリーダー配列を有するbcrトランスジェニックマウス |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100205682A1 (en) | 2010-08-12 |
| ES2473596T3 (es) | 2014-07-07 |
| EP1644417A2 (en) | 2006-04-12 |
| EP1644417B1 (en) | 2014-04-30 |
| CA2532117C (en) | 2012-07-10 |
| WO2005007696A2 (en) | 2005-01-27 |
| US8652842B2 (en) | 2014-02-18 |
| US8410333B2 (en) | 2013-04-02 |
| JP6017763B2 (ja) | 2016-11-02 |
| JP2011182801A (ja) | 2011-09-22 |
| US20060026696A1 (en) | 2006-02-02 |
| CN103205436B (zh) | 2016-05-25 |
| IL172885A0 (en) | 2006-06-11 |
| MXPA06000562A (es) | 2006-03-30 |
| US7585668B2 (en) | 2009-09-08 |
| CA2532117A1 (en) | 2005-01-27 |
| US20130189774A1 (en) | 2013-07-25 |
| AU2004257292A1 (en) | 2005-01-27 |
| USRE47131E1 (en) | 2018-11-20 |
| WO2005007696A3 (en) | 2005-11-03 |
| CN1852925A (zh) | 2006-10-25 |
| CN103205436A (zh) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6017763B2 (ja) | ヒト化免疫グロブリン遺伝子座 | |
| JP7236409B2 (ja) | ヒトλ可変領域およびマウス定常領域を含む軽鎖を発現するマウス | |
| US7129084B2 (en) | Production of humanized antibodies in transgenic animals | |
| EP2931030B1 (en) | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same | |
| US20050153392A1 (en) | Transgenesis with humanized immunoglobulin loci | |
| US8354568B2 (en) | Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin | |
| AU2001284703A1 (en) | Production of humanized antibodies in transgenic animals | |
| KR20110089846A (ko) | 키메라 항체의 제조를 위한 인간 이외의 포유동물 | |
| EP1690934A2 (en) | Generation of xenogeneic antibodies | |
| CN118140872A (zh) | 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体 | |
| HK40029423A (en) | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same | |
| HK40029423B (en) | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same | |
| ZA200301723B (en) | Production of humanized antibodies in transgenic animals. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20081212 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100629 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100928 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101115 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110614 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110808 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110811 |